65,437 trials
Colorectal Cancer
Primary: Percentage of Participants Without Detectable Metastatic Disease After Secondary Resection Post Surgery — 84.6 Percentage of participants
COPD · Emphysema · Chronic Bronchitis
Primary: Change in Percent Emphysema on CT Scan — -0.32; 2.18 % Emphysema Whole Lung — p=0.06
Bipolar Disorder · Depression
Primary: Depressive Relapse — 3; 4 Participants
PTSD · TBI (Traumatic Brain Injury)
Primary: Functional Magnetic Resonance Imaging (fMRI) Correlation — .21; .19; .36 r-value
Arthritis, Rheumatoid
Primary: Number of Participants With Adverse Events — 143; 154; 26; 16 participants
Diabetes · Hyperglycemia · Surgical Site Infection
Primary: Number of Participants Undergoing Open Heart Surgery With Postoperative Surgical Site Infection — 4; 5; 5 participants — p=0.512
Primary Immunodeficiency Diseases (PID)
Primary: Number of Related Systemic Adverse Events (Excluding Infections) — 59 adverse events
Sepsis
Primary: CoQ10 Levels — 0.38; 0.87 (mcg/mL)
Central Retinal Vein Occlusion
Primary: Average Change in Visual Acuity (Letters) From Baseline to Month 1 Through Month 3 — 11.3; -2.7 Letters — p=<0.001
Migraine Headache
Primary: Pain-Relief at 2 Hours Post-treatment — 56; 65; 66 Participants
Peripheral Pulmonary Nodules
Primary: Feasibility — 24 participants
Cocaine Dependence · Opioid Dependency
Primary: Change of Thrice Weekly Cocaine Free Urine Toxicology From Week 1 to 13 — 6; 0; 3; 2 participants that were cocaine free — p=0.09
Lung Cancer
Primary: Progression-free Survival — 3.7; 2.8; 4.1 months
Asthma
Primary: Indirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP) — 253.3; 70.4; 16.9; 17.1 US Dollars
Hypoglycemia
Primary: Number of Subjects With Plasma Glucose > 70 mg/dL at 30 Minutes Post-treatment — 7; 6 participants with positive response